Trials / Completed
CompletedNCT01705223
Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan)
Phase IIa Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- National Center for AIDS/STD Control and Prevention, China CDC · Other Government
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This trial studies the safety and immunogenicity of a HIV clade B'/C DNA vaccine followed by recombinant vaccinia virus rTV boost in HIV-uninfected healthy volunteers at low or high risk of HIV infection. In addition, the effect of different intervals of the prime-boost will be studied.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | DNA vaccine | 4mg/dose, three doses at week 0,4,8 |
| BIOLOGICAL | DNA vaccine prime with the addition of electroporation | 4mg/dose, three doses at week 0,4,8 |
| BIOLOGICAL | rTV boost | at week 16 |
| BIOLOGICAL | rTV boost | at week 24 |
| BIOLOGICAL | rTV boost | at week 32 |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2014-10-01
- Completion
- 2015-01-01
- First posted
- 2012-10-12
- Last updated
- 2015-05-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01705223. Inclusion in this directory is not an endorsement.